Measles Resurgence and Drug Development

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• Measles caused over a million deaths annually before vaccination, but progress in reducing case-fatalities has stalled around 100,000 deaths per year.
• A 2019 resurgence highlights ongoing threats and the need for enhanced control strategies beyond current vaccination efforts.
• While measles eradication is feasible, achieving elimination may require novel approaches due to persistent challenges.

Purpose of the Study:

• To investigate the potential role of antiviral therapeutics in augmenting measles control.
• To identify obstacles hindering the development of anti-measles and anti-paramyxovirus drugs.
• To define essential drug properties for effective measles treatment and clinical testing.

Main Methods:

• Literature review of existing research on measles, paramyxoviruses, and antiviral drug development.
• Analysis of challenges specific to measles virus (MeV) clinical testing.
• Definition of ideal characteristics for novel anti-measles therapeutics.

Main Results:

• No drugs are currently approved for measles or other paramyxovirus infections, indicating a significant gap in treatment options.
• Development of anti-paramyxovirus drugs faces hurdles including specific clinical testing challenges for MeV.
• Key drug properties are needed to overcome these obstacles and facilitate effective treatment.

Conclusions:

• Antiviral therapeutics could potentially complement vaccination efforts to address stalled progress in measles control.
• Overcoming drug development and clinical testing obstacles is crucial for advancing measles treatment.
• Defining suitable drug properties is a necessary step towards developing effective antiviral therapies for measles.